Analysis of 269 Cases of Uterus-Preserving U-Surgery for Diffuse Adenomyosis in Patients Outside Chinese Mainland
Hong-Xia Wang （ Zhengzhou 460 Hospital, Zhengzhou, Henan,450002, China ）
Ya-Qin Zhang （ Zhengzhou 460 Hospital, Zhengzhou, Henan,450002, China ）
Yue-Yue Liu （ Zhengzhou 460 Hospital, Zhengzhou, Henan,450002, China ）
Yao Jia （ Zhengzhou 460 Hospital, Zhengzhou, Henan,450002, China ）
Bin Wang （ INTERNATIONAL HOSPITAL OF ZAMBIA,30079, Fairview, Lusaka, Zambia ）
https://doi.org/10.37155/3060-8708-0301-4Abstract
Objective: To analyze the clinical data of 269 patients with diffuse adenomyosis outside Chinese Mainland who underwent uterus-preserving U-surgery from 2006 to 2025, evaluate the safety, symptom improvement effect and long-term recurrence rate of the surgical procedure, and explore its international clinical application value. Methods: The clinical data of 269 patients with diffuse adenomyosis from 22 countries worldwide were collected retrospectively. The age, disease course, previous treatment history, surgery-related indicators, postoperative visual analog scale (VAS) score for dysmenorrhea, menstrual volume changes and recurrence were statistically analyzed using SPSS 26.0. Results: The patients were aged 22 to 53 years, with a mean age of (37.5±6.2) years; the disease course was 3 to 22 years, with a mean of (8.6±3.5) years. A total of 222 cases (82.5%) had received conservative treatments such as GnRH-a and progestogens, and 33 cases (12.3%) had a history of recurrence after focal resection. The operation time was 58 to 196 minutes, with a mean of (102.5±28.6) minutes; the intraoperative blood loss was 200 to 500 ml, with a mean of (320.5±85.2) ml, and all incisions achieved primary healing. The mean preoperative VAS score for dysmenorrhea was 8.6 points, which decreased to 1.5 points after surgery, with a highly statistically significant difference (P
Keywords
Diffuse adenomyosis; Uterus-preserving U-surgery; Uterus preservation; Dysmenorrhea; Recurrence rate; International patientsFull Text
PDFReferences
[2] Lang J H, Leng J H. Interpretation of the Expert Consensus on the Diagnosis and Treatment of Adenomyosis (2022 Edition) [J]. Chinese Journal of Obstetrics and Gynecology, 2022, 57(12): 889-892.
[3] Li X M, Yang Y B. Current status and progress of drug therapy for adenomyosis [J]. Chinese Journal of Practical Gynecology and Obstetrics, 2021, 37(5): 523-527.
[4] Chen C L, Liu P. Clinical application and thinking of minimally invasive interventional therapy for adenomyosis [J]. Chinese Journal of Radiology, 2020, 54(8): 801-804.
[5] Shen K, Ma D. Gynecology and Obstetrics [M]. 9th ed. Beijing: People's Medical Publishing House, 2018: 275-278.
[6] Wang B. Clinical innovation and application of uterus-preserving surgery for adenomyosis [J]. Chinese Journal of Clinical Obstetrics and Gynecology, 2023, 24(3): 225-227.
[7] Zhu L, Fan Q B. Current status and development trend of global diagnosis and treatment of adenomyosis [J]. International Journal of Obstetrics and Gynecology, 2024, 51(3): 291-295.
[8] Chen L J, Lin J. Application of GnRH-a in the treatment of adenomyosis and management of adverse reactions [J]. Clinical Medication Journal, 2022, 20(7): 1-5.
[9] Li X L, Wu X K. Research progress of surgical treatment for adenomyosis [J]. Maternal and Child Health Care of China, 2021, 36(19): 4576-4579.
[10] Liu J Y, Qian X Q. Balanced strategy between female fertility protection and gynecological disease treatment [J]. Chinese Journal of Reproduction and Contraception, 2022, 42(5): 501-505.
[11] WANG B. Efficacy of U-shaped uterine-sparing surgery for diffuse adenomyosis: A 20-year clinical study[J]. Journal of Minimally Invasive Gynecology, 2025, 32(4): 689-696.
[12] LI J J, CHUNG J P W. The investigation and management of adenomyosis in women who wish to improve or preserve fertility[J]. Human Reproduction Update, 2023, 29(4): 678-695.
[13] VANNUCCINI S, PETRAGLIA F. Recent advances in understanding and managing adenomyosis[J]. F1000Research, 2019, 8:283.
[14] ANTERO M F, AYHAN A. Pathology and pathogenesis of adenomyosis[J]. Seminars in Reproductive Medicine, 2020, 38(2-3):108-118.
[15] ETRUSCO A, BARRA F. Current medical therapy for adenomyosis: from bench to bedside[J]. Drugs, 2023, 83(17):1595-1611.
[16] PAL S, BHATTACHARYA S. Microwave ablation of diffuse uterine adenomyosis: a novel minimally invasive fertility preserving therapeutic approach[J]. Journal of Gynecologic Surgery, 2025, 41(3):189-195.
[17] MOAWAD G, YOUSSEF Y. The impact of conservative surgical treatment of adenomyosis on fertility and perinatal outcomes[J]. Journal of Clinical Medicine, 2024, 13(12):2531.
[18] NIRGIANAKIS K, KALAITZOPOULOS D R. Fertility, pregnancy and neonatal outcomes of patients with adenomyosis: a systematic review and meta-analysis[J]. Reproductive Biomedicine Online, 2021, 42(2):185-206.
[19] HADISAPUTRA S, AL-JAMA M. GnRH-a therapy for adenomyosis: a randomized control trial[J]. Journal of Obstetric, Gynecologic, & Neonatal Nursing, 2020, 49(3):345-353.
[20] CAPEZZUOLI T, ORLANDI G. Gynaecologic and systemic comorbidities in patients with endometriosis and adenomyosis: impact on quality of life[J]. Clinical and Experimental Obstetrics & Gynecology, 2022, 49(7):1571-1576.
Copyright © 2026 Hong-Xia Wang,Ya-Qin Zhang,Yue-Yue Liu,Yao Jia,Bin Wang
Publishing time:2026-02-28
This work is licensed under a Creative Commons Attribution 4.0 International License